Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

NEW YORK : Pfizer reported better than expected quarterly profits today behind cost cuts and growth in some non-Covid-related ...

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.

Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds itself at a critical juncture as it navigates a complex landscape of ...